SGN CD19B

Drug Profile

SGN CD19B

Alternative Names: SGN-CD19B

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals; Seattle Genetics
  • Developer Seattle Genetics
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Mar 2016 Pharmacodynamics data from a preclincial trial presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH-2015)
  • 25 Feb 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02702141)
  • 29 Oct 2015 Preclinical trials in Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top